Physician profile
Kaman Ng
NPI 1982603411
$4,125.50
in general payments reported to CMS, 2019-2025
24 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,264 · 2020: $167 · 2021: $288 · 2022: $120 · 2023: $670 · 2024: $474 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,187 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,186.98 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $843.66 | 2019-2023 | Uptravi, Opsumit |
| Amgen INC. | $449.31 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $384.50 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.92 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $277.12 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $243.11 | 2019-2024 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $239.35 | 2019 | |
| Pfizer INC. | $221.84 | 2019-2021 | |
| Amarin Pharma, INC. | $151.68 | 2019-2020 | |
| Boston Scientific Corporation | $146.45 | 2024 | Watchman Flx |
| Madrigal Pharmaceuticals | $135.15 | 2024 | Rezdiffra |
| Merck Sharp & Dohme LLC | $125.00 | 2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $92.51 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $67.94 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $65.30 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $60.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $56.40 | 2023-2024 | Austedo, Austedo Xr |
| Atricure, INC. | $52.27 | 2019 | |
| Novo Nordisk INC | $51.77 | 2021-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $49.74 | 2019 | |
| Edwards Lifesciences Corporation | $44.76 | 2019 | |
| Astellas Pharma US INC | $33.86 | 2019 | |
| Abbott Laboratories | $24.84 | 2019 | |
| Preventice Services, LLC | $14.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaman Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.